This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NORD To Honor Rare Disease Heroes At 30th Anniversary Celebration

Momentous Event to Highlight Historic Past, Promising Future

WASHINGTON, April 5, 2013 /PRNewswire-USNewswire/ -- Honoring heroes of the past and innovators of the future, the National Organization for Rare Disorders (NORD) will host a 30 th Anniversary Celebration for the entire rare disease community on Tuesday, May 14 at the Mellon Auditorium in Washington, DC.  This momentous occasion will provide an exciting opportunity to celebrate the history and lasting impact of both the Orphan Drug Act and NORD.

"Since 1983, the rare disease community, with NORD as a unifying force, has built a solid foundation of accomplishment," said NORD President and CEO Peter L. Saltonstall.  "We look forward to honoring heroes from all sectors of the community.  And we also anticipate an evening that will inspire future innovation as we hear first-hand from patients and families living with rare diseases."

The Orphan Drug Act of 1983 launched a new era in the development of therapies for people with rare diseases.  Established by patient advocates at the time the law was enacted, NORD has been at the heart of rare disease activity over the years, working with partners in patient organizations, government and industry to bring meaningful advancements for patients.

Honorees for the NORD 30 th Anniversary Celebration will be:

For Leadership in Public Policy

These awards honor public officials for leadership that has improved the lives of millions of Americans living with rare diseases.
  • William Corr, Deputy Secretary, U.S. Department of Health and Human Services
  • The Honorable Nancy Kassebaum, U.S. Senate, retired
  • The Honorable Henry Waxman, U.S. House of Representatives

For Vision and Pioneering Guidance

These awards honor pioneers in the patient community, government and industry for years of service to rare disease patients and their families.
  • Stephen C. Groft, PharmD
  • Marlene Haffner, MD, MPH
  • Lars Uno Larsson
  • Abbey S. Meyers
  • Jess G. Thoene, MD

For Innovative Orphan Products Approved in 2012

These awards honor companies that brought important and innovative treatments to market during the previous year.
  • Aegerion Pharmaceuticals, Inc.
  • NPS Pharmaceuticals, Inc.
  • Onyx Pharmaceuticals, Inc.
  • Sigma-Tau Pharmaceuticals, Inc.


Registration and sponsorship information is available on the NORD website (   

SOURCE National Organization for Rare Disorders (NORD)

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.70 -0.60%
FB $101.91 0.90%
GOOG $681.92 -0.32%
TSLA $150.47 4.73%
YHOO $26.75 -1.30%


Chart of I:DJI
DOW 15,660.18 -254.56 -1.60%
S&P 500 1,829.08 -22.78 -1.23%
NASDAQ 4,266.8370 -16.7550 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs